19 チャンネル。 BTS、4月19、20日にYouTube公式チャンネル‘BANGTANTV’で『BANG BANG CON』を配信|株式会社HYBE LABELS JAPANのプレスリリース

Conclusions We report the first case of COVID-19 post vaccine associated GBS. Case presentation An 82-year-old highly functional female at baseline without significant comorbidities presented to the emergency department with generalized body aches, paresthesia, and difficulty walking. The patient had areflexia in both upper and lower extremities. Her sensation to light touch was intact in bilateral upper and lower extremities but decreased to pinprick in bilateral lower extremities up to the knees. Inside the human body, mRNA enters the human cell and instructs the cells to identify the spike protein found on the surface of SARS-COV-2, the virus that causes COVID-19. The patient reported generalized malaise and body aches during the first week after receiving her vaccination. No dysmetria was noted on finger to nose testing. We encourage and support the recommendations of the CDC and WHO guidelines for COVID-19 vaccination. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. A lumbar puncture was performed and cerebrospinal fluid analysis showed albuminocytologic dissociation protein of 88 and WBC of 4 , consistent with the diagnosis of GBS. Coronavirus Cov-2 PCR was negative. She developed back pain and MRI lumbar spine demonstrated the enhancement of cauda equina nerve roots also consistent with the diagnosis of GBS see Figure. Later, if these antibodies encounter the actual virus, they are ready to recognize and kill the virus before it can cause illness. However, during the second week, she had worsening symptoms and noticed increased difficulty in walking to the point where she had to use a walker for ambulation. She was referred to the outpatient Neurology Clinic for follow up Nerve Conduction Study NCS and electromyography EMG to be done in three to four weeks. However, Guillain-Barre Syndrome GBS after receiving COVID-19 vaccine has not been reported to date February 2, 2021 to the best of our knowledge. She received her first dose of the Pfizer COVID vaccine two weeks prior to presentation see Figures ,. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. No complications were observed during or after the treatment. Since the first case of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 was reported in Wuhan, China, in December 2019, Coronavirus - 19 COVID-19 has become a global pandemic with multiple neurological complications. In December 2020, the FDA approved two vaccines for the prevention of COVID-19 infection. The Centers for Disease Control CDC was notified about this complication associated with the vaccination. In December 2020, two vaccines have been approved in the United States for the prevention of COVID-19. All content published within Cureus is intended only for educational, research and reference purposes. The COVID-19 vaccines approved by the FDA are synthetic messenger RNA vaccines also called mRNA vaccines. GBS is one of the few leading causes of acute flaccid paralysis in developed countries and can present with varying degrees of weakness, sensory abnormalities, and autonomic dysfunction. The patient was admitted to the Neurology unit and started on intravenous immunoglobulin IVIG. We report a case of Guillain-Barre Syndrome GBS after receiving the first dose of Pfizer - COVID-19 vaccine. The patient received physical therapy during the hospital stay and was discharged to acute rehabilitation facility. The patient did not show any signs of respiratory compromise and clinical improvement was appreciated after three doses of IVIG, the patient completed five days of IVIG. Our bodies then recognize the spike protein as an invader and produce antibodies against it. Routine labs were unrevealing. In this pandemic and with ongoing worldwide mass vaccination campaign, it is critically important for clinicians to rapidly recognize neurological complications or other side effects associated with COVID-19 vaccination. Understanding the epidemiology of the disease and the adverse events arising because of the vaccination is crucial. Do not disregard or avoid professional medical advice due to content published within Cureus. We would like to highlight that the risk of neurological complications or any other adverse effect associated with COVID-19 vaccination is low and the benefits of the vaccination outweigh any potential risks or side effects, both at the individual and society levels. In some patients, this immune response can trigger autoimmune processes that lead to the production of antibodies against the myelin and cause GBS. The patient then subsequently sustained a fall due to her weakness, which prompted her visit to the emergency room. The patient developed labile blood pressure on day 2 that resolve before discharge. She had an unremarkable cranial nerve examination and no visible facial weakness or asymmetry was appreciated. Her physical examination on presentation revealed normal mental status and speech. We report the first reported case of GBS after receiving the first dose of Pfizer COVID-19 vaccine.。 。 。

。 。 。

。 。 。

9

。 。

。 。 。

4